Business Context and Reporting Period
Company: Repro-Med Systems, Inc. (Note: Metadata listed "KORU Medical Systems, Inc." but the filing text identifies the registrant as Repro-Med Systems, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: August 31, 2012
Business Overview: The Company designs, manufactures, and markets proprietary medical devices for the ambulatory infusion market and emergency medical applications. Key products include the FREEDOM60® Syringe Infusion Pump and the RMS HIgH-Flo® Subcutaneous Safety Needle Sets. The Company is classified as a smaller reporting company.
Key Financial Metrics
| Metric | Three Months Ended Aug 31, 2012 | Six Months Ended Aug 31, 2012 |
|---|---|---|
| Net Sales | $1,951,608 | $3,695,773 |
| Net Income | $350,644 | $440,983 |
| Net Operating Profit | $541,993 | $688,114 |
| Gross Profit Margin | 65.9% | 64.7% |
| Cash and Cash Equivalents (End of Period) | $1,684,369 | |
| Total Assets | $5,211,276 | |
| Total Liabilities | $1,219,565 | |
| Net Cash Provided by Operating Activities (6 Months) | $377,384 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 43.3% for the three months and 29.4% for the six months ended August 31, 2012, compared to the prior year periods. This was driven by substantial increases in sales of the RMS HIgH-Flo® Subcutaneous Safety Needle Sets and improved sales of the FREEDOM60® line in domestic and international markets.
- Profitability: Net income surged 197.0% for the quarter and 39.5% for the six-month period. Net operating profit increased significantly due to higher sales volume and improved gross profit margins (65.9% vs. 63.8% for the quarter).
- Expenses:
- Cost of Goods Sold (COGS): Increased 35.1% (quarter) and 26.2% (six months) due to higher sales volume, expanded production payroll, and the addition of a night shift.
- Selling, General and Administrative (SG&A): Increased 1.1% for the quarter and 24.3% for the six months, attributed to added sales/marketing staff and increased marketing/trade show expenses, partially offset by a non-recurring CEO bonus paid in the prior year.
- Research and Development (R&D): Increased 271.3% for the quarter and 232.2% for the six months, primarily due to new product development for the RMS HIgH-Flo® sets and manufacturing improvements.
- Capital Expenditures: Net cash used in investing activities was $428,820 for the six months, primarily due to $427,692 in payments for property and equipment, including the acquisition of a residence adjacent to the facility for office/R&D space.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management states that with current capital and increasing sales, the Company expects to meet or exceed liquidity needs for the next twelve months.
- Product Strategy: Continued focus on marketing FREEDOM60® and RMS HIgH-Flo® through trade shows and advertising. The Company is pursuing direct sales into the hospital market and expanding distribution in the respiratory market.
- Regulatory and Reimbursement:
- Received FDA approval for the RMS HIgH-Flo® Subcutaneous Safety Needle Sets in May 2011.
- Secured a favorable Medicare HCPCS code (E0779) for the FREEDOM60®, significantly increasing reimbursement for billable syringe pump applications.
- Risks and Contingencies:
- Competition: Faces competition from electrically powered devices (e.g., Laerdal's V-Vac®) and potential new market entrants.
- Reimbursement: Sales are heavily dependent on Medicare reimbursement policies, which could change adversely.
- Inventory: Inventory includes $349,000 of subassemblies rejected for not meeting specifications, currently being returned to vendors.
- Related Party Transactions: The Company leases an aircraft from a company controlled by the President.
Investor Verification Checklist
- Inventory Quality: Verify the status and recoverability of the $349,000 in rejected subassemblies noted in the inventory notes.
- Reimbursement Stability: Confirm the long-term stability of the E0779 Medicare code and its impact on FREEDOM60® revenue.
- Related Party Leases: Review the terms of the month-to-month aircraft lease with the President's controlled entity.
- Capital Expenditure ROI: Assess the utilization and return on the recent $427,692 investment in property and equipment.
- Deferred Compensation: Review the amortization schedule for the $263,700 deferred compensation cost associated with the July 2012 employee stock authorization.